Financials • Specialty Insurers
$43.28 ▲ +0.66
(+1.55%)
MKT CAP: $11.07B • VOL: 1.99M
52W L $29 52W H $59
RYAN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.99B | $2.46B | $2.03B |
| YoY Revenue Growth % | +21.9% | +21.2% | — |
| Gross Profit | $1.32B | $1.08B | $891.7M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $493.6M | $427.8M | $359.1M |
| Operating Margin % | 16.5% | 17.4% | 17.7% |
| Net Income (GAAP) | $63.4M | $94.7M | $61.0M |
| EBITDA (Normalized) | $601.4M | $516.2M | $432.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $643.7M | $514.9M | $477.2M |
| Capital Expenditures (CapEx) | $134.8M | $110.5M | $91.2M |
| Free Cash Flow (FCF) | $508.9M | $404.4M | $386.0M |
| FCF Margin % | 17.0% | 16.5% | 19.0% |
| Return on Invested Capital (ROIC %) | 10.3% | 10.2% | 7.7% |
| Cash & Short-Term Equivalents | $158.3M | $540.2M | $669.8M |
| Total Debt (Short + Long Term) | $3.29B | $3.23B | $1.42B |
| Total Stockholders' Equity | $648.1M | $627.7M | $2.92B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RYAN.